Lupin Limited’s recent settlements give investors as much reason to cheer as to be concerned. A $253.2m provision for a settlement related to antitrust class actions filed in the Northern District of California regarding Glumetza (metformin) led the company to report a fiscal second quarter loss of INR14.7bn ($196.4m).
A group of Glumetza purchasers had alleged that Lupin agreed to delay the launch of its generic by four years in exchange for $3m in cash and an agreement by the originator parties not to market an authorized generic to compete with the Indian company, which subsequently saw a price hike of
